When You Design the Test Before You Build the Product

A specialist surgical robotics company produced a clean first-in-human disclosure on May 6, on a 50-patient study designed years earlier against the specific endpoints the regulatory pathway and the strategic-acquirer evaluation actually read. The same day the FDA warned of a national supply shortage running through year-end on a disposable medical product whose entire U.S. supply traced back to a single supplier whose remediation event removed the inventory across an entire procedural specialty. The next day a global diagnostics company announced a $1.05 billion deal to acquire an AI software firm whose value to the acquirer compounded over a five-year operating partnership rather than over a standalone product cycle. Read across the three disclosures, the structural lesson for founders running businesses in any industry is consistent. The companies that produce the outcome you want three years from now design the test before they build the product, build the supply architecture before the single-supplier disruption arrives, and run the strategic-partnership operating cadence before the strategic conversation. Understanding the visible win that lands this quarter is only part of the job. Doing the architectural work years earlier that produces the win at all is one of the strategic problems The Build exists to help you think through.

Design the Test Before You Build the Product

Every business that produces a clean visible win three to four years from now is designing the test the win will be measured against right now. The pattern repeats across industries. The software company whose product wins a procurement evaluation in 2029 is the one that read the buyer’s evaluation rubric in 2026, designed the product against the specific criteria the buyer actually scores, and built the evidence base, the customer references, and the operating profile against the test the buyer runs rather than against the test the engineering team is most comfortable supporting. The consumer brand that lands a major retail placement in 2029 is the one that read the retailer’s category review process in 2026, designed the product, the packaging, the supply commitments, and the marketing posture against the specific criteria the buyer evaluates, and built the brand and operating profile against the test the category review runs. The services business that gets acquired at a strategic multiple in 2029 is the one that read what the strategic acquirers in the category actually buy in 2026, designed the methodology, the senior-talent pipeline, the client portfolio composition, and the operating systems against the profile the acquirer prices, and built the diligence-ready posture against the test the acquirer runs.

The default first-time founder runs the operation in the opposite order. The product gets built against the technical vision the engineering team is most confident in, the operating profile gets shaped by the year-by-year pressure of running the business, and the test gets read at the moment the test arrives. The founder finds out at the procurement evaluation that the buyer wanted a different security architecture than the team designed against, finds out at the retail category review that the buyer wanted a different price point and a different supply commitment than the brand committed to, and finds out at the strategic conversation that the acquirer prices a different operating profile than the founder built the business against. The cost of finding out late is the difference between the visible win the business actually produces and the visible win the operating plan modeled.

The founders who produce the clean visible win do the opposite. They identify the test the visible win will be measured against three to four years before the test arrives, design the product and the operating profile backwards from the specific criteria the test reads, and build the architectural and partnership work that compounds through the build years into the integrated profile the test prices at the premium multiple. The Neptune Medical CARE 1 first-in-human disclosure on May 6 is the cleanest current public example of what the discipline produces. The 100% cecal intubation rate and zero device-related adverse events lined up because the study was designed years earlier against the specific endpoints the regulatory pathway and the strategic-acquirer evaluation actually read, with the procedural variety, the follow-up window, and the site selection aligned to the route the platform was always going to take.

Build the Supply Architecture Before the Disruption Arrives

Every business that depends on inputs sourced from a small number of suppliers is exposed to a single-supplier disruption scenario the operating plan typically has not priced. The pattern repeats across industries. The software company that runs core infrastructure on a single cloud region absorbs a multi-day customer-facing outage when the region goes down. The consumer brand that sources a single ingredient or component from one supplier absorbs a six-month inventory disruption when the supplier’s quality event removes the input from market. The services business that depends on one referral channel for the bulk of new client flow absorbs a revenue cliff when the channel reprices or restructures. The medical device platform that depends on a single supplier for a disposable input across a procedural specialty absorbs a procedure-volume cliff when the supplier’s remediation event removes the input across the customer base.

The FDA Letter to Health Care Providers on May 6 is the cleanest current example of what single-supplier exposure costs when the disruption arrives. A March recall by one supplier on neurosurgical sponges and patties removed a major share of the U.S. supply for the disposable products neurosurgeons use to absorb fluid and protect tissue during cranial and spinal procedures, and the agency now expects the shortage to continue through year-end. The platforms running neurosurgical procedures on integrated robotics or navigation systems lose procedure volume on every case the disposable shortage takes off the schedule, and the procedure-volume cliff arrived without warning from a supply concentration the operating plan was not stress-testing against.

The founders who get the supply architecture right run the operation in the opposite order. They map the supply architecture against credible single-supplier disruption scenarios across every input the business depends on, diversify the supply base across the inputs whose disruption would produce a customer-facing or revenue cliff, build contractual and inventory protections against the disruption arriving in a quarter the business has no margin to absorb it, and resource the supply diversification work as a Day-1 operating line rather than as an expense the business runs to once the disruption is already in motion. The compensation arrives at the moment the single-supplier disruption hits the industry and the business absorbs it without the customer-facing cliff, while the cohort running supply concentrated at the single-supplier level loses revenue or procedure volume across the planning year.

Run the Partnership Before You Need It

Every business that produces a strategic transaction at a premium multiple in 2029 is running the operating partnership that produces the multiple right now. The pattern repeats across industries. The software company whose acquirer pays the integrated-stack premium in 2029 is the one that ran a five-year operating partnership with the acquirer through the build phase, integrated the product, the data, the workflow, and the customer base before the strategic conversation, and arrived at the conversation with a partnership history the buyer already prices. The consumer brand that gets acquired at a category premium in 2029 is the one that built the retail relationship, the supply commitment, the brand operating partnership, and the integrated marketing motion across multiple years of the build phase. The services business that produces the strategic premium in 2029 is the one that built the referral partnership, the methodology integration, the senior-talent overlap, and the operating-cadence history across multiple years before the strategic conversation. The medical device or AI-medical platform that produces the integrated-stack premium in 2029 is the one that ran the operating partnership with the strategic acquirer through the build phase, integrated the platform with the acquirer’s clinical, diagnostic, or therapeutic stack, and arrived at the strategic conversation with a partnership history the buyer already prices at the integrated-stack multiple rather than at the standalone capability multiple.

The Roche-PathAI deal on May 7 is the cleanest current public example of what the integrated-partnership multiple costs when the acquirer prices it. Roche agreed to acquire PathAI for up to $1.05 billion, structured as $750 million upfront and up to $300 million in milestones, building on a five-year partnership that began in 2021 and expanded in 2024 to include co-developed AI-enabled companion diagnostic algorithms. The price reflects the integrated AI-diagnostics stack the partnership produced, not the standalone AI software capability the acquirer could have bought through a smaller transaction on the open market. The founders who get the strategic-partnership question right start the operating cadence with the prospective acquirer in the build years before the strategic conversation arrives, resource the integration work as a Day-1 strategy line rather than as a corporate-development project the business runs once the strategic conversation is already in motion, and arrive at the conversation with a partnership history the acquirer prices at the integrated-stack multiple.

The Build covers this kind of structural strategic question in practical terms for founders running real businesses. Which visible win do you want to produce three years from now? What test will the win be measured against, and which architectural and product decisions need to be designed backwards from the test? Which inputs in your supply architecture would produce a customer-facing cliff if the single supplier had a disruption next quarter, and which protections need to be in place before the disruption arrives? Which strategic-partnership operating cadence are you running with the prospective acquirers and customers whose evaluation produces the visible win three years from now, and how much partnership history does the business need to compound through the build years to arrive at the strategic conversation with the integrated-profile multiple rather than the standalone-capability multiple?